Lilly Announces Deal to Train Minority Clinical Trial Investigators


, Roswell Park Cancer Institute Partner to
First-of-its-kind program aims to help improve diversity in clinical trials

INDIANAPOLIS and BUFFALO, N.Y., Aug. 1, 2013 /PRNewswire/ — In an effort to increase the number of minority investigators in clinical research, Eli Lilly and Company (NYSE: LLY) and The Center for Drug Development and Clinical Trials at Roswell Park Cancer Institute (RPCI) today announced a new collaborative training program specifically tailored to this growing group of investigators. This program is the first of its kind in the industry.

The partnership will include a three-day clinical research workshop, “Reducing Cancer Disparities Through the Training of a Diverse Workforce,” for minority physicians across the country. Workshops will begin in spring 2014 and will run through 2016.

There are approximately 10,400 oncologists in the United States, but approximately 1 to 2 percent are African American and approximately 2 to 3 percent are Hispanic. The goal of the new initiative is to train 75 to 150 oncologists in the conduct of clinical trials.

“Providing patients with access to new and innovative therapies is one of the most crucial issues in oncology,” said workshop director Alex A. Adjei, M.D., Ph.D., F.A.C.P., senior vice president for clinical research and director of the Center for Drug Development at Roswell Park. “But we can’t provide that access fairly and

Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS